IN THE CLAIMS

Please amend the claims as shown below.

1. (Previously Presented) A substantially purified nucleic acid encoding a pentapeptide ~~having~~ consisting of an amino acid sequence of Asp-Ile-Leu-Arg-Gly (SEQ ID NO:1).

2. (Canceled)

23. (Previously Presented) The substantially purified nucleic acid as set forth in claim 1, wherein the pentapeptide is obtained from pre-larvae of *Antheraea yamamai*.

34. (Previously Presented) A substantially purified dormancy-control pentapeptide having an amino acid sequence of Asp-Ile-Leu-Arg-Gly (SEQ ID NO:1), a molecular weight of 570.959 Da and dormancy-control activity, wherein the C-terminal is amidated.

45. (Previously Presented) The dormancy-control pentapeptide as set forth in claim 4, wherein the dormancy-control pentapeptide is obtained from pre-larvae of *Antheraea yamamai*.

56. (Previously Presented) A method for preparing a dormancy-control pentapeptide, comprising the steps of

adding an acid-methanol solution consisting of methanol: water: acetic acid to pulverized pre-larvae of an insect;

triturating the resulting mixture;

centrifuging the mixture; and

subjecting the resulting supernatant to reverse phase high performance liquid chromatography and mixing-separation mode high performance liquid chromatography to give a dormancy-control pentapeptide, which has an amino acid sequence of Asp-Ile-Leu-Arg-Gly (SEQ ID NO:1) and a molecular weight of 570.959 Da, wherein the C-terminal is amidated.

6 7. (Currently Amended) A composition comprising a physiologically acceptable carrier and, as an effective component, a pentapeptide having an amino acid sequence of Asp-Ile-Leu-Arg-Gly (SEQ ID NO:1)~~,~~ and a molecular weight of 570.959 Da, wherein the C-terminal is amidated.

8. (Canceled)

7 ~~8~~. (Currently Amended) The composition as set forth in claim 7 ~~or 8~~, wherein the pentapeptide is obtained from pre-larvae of *Antheraea yamamai*.

8 ~~10~~. (Previously Presented) A composition comprising a physiologically acceptable carrier and, as an effective component, a tetrapeptide having an amino acid sequence of Ile-Leu-Arg-Gly (SEQ ID NO:2) and a molecular weight of 456.58 Da, wherein the C-terminal is amidated.

11. (Canceled)

9 ~~12~~. (Currently Amended) The composition as set forth in claim ~~10 or 11~~ 7, wherein the tetrapeptide is obtained from pre-larvae of *Antheraea yamamai*.

10 ~~13~~. (Previously Presented) A substantially purified pentapeptide having an amino acid sequence of Asp-Ile-Leu-Arg-Gly (SEQ ID NO:1).

14-17. (Canceled)

11 ~~18~~. (Previously Presented) A substantially purified tetrapeptide having an amino acid sequence of Ile-Leu-Arg-Gly (SEQ ID NO:2).

12 ~~19~~. (Previously Presented) A substantially purified tetrapeptide having an amino acid sequence of Ile-Leu-Arg-Gly (SEQ ID NO:2), wherein the C-terminal is amidated.